12 reports of this reaction
4.4% of all AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE reports
#4 most reported adverse reaction
MALIGNANT MELANOMA is the #4 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, manufactured by Kenvue Brands LLC. There are 12 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE to MALIGNANT MELANOMA. This represents approximately 4.4% of all 273 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE who experience malignant melanoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT MELANOMA is moderately reported among AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE users, representing a notable but not dominant share of adverse events.
In addition to malignant melanoma, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE:
The following drugs have also been linked to malignant melanoma in FDA adverse event reports:
MALIGNANT MELANOMA has been reported as an adverse event in 12 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT MELANOMA accounts for approximately 4.4% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, making it a notable side effect.
If you experience malignant melanoma while taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.